On October 10, 2023, the U.S. Food and Drug Administration (FDA) issued a public warning regarding the potential health risks associated with compounding ketamine products. This particular warning follows an FDA alert issued on February 16, 2022, regarding the potential risks associated with ketamine nasal spray. The October 10, 2023, FDA warning noted that even though there has been widespread marketing for ketamine to treat psychiatric disorders, such as depression, anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder, the FDA has not approved ketamine for these types of psychiatric disorders.
The FDA’s alert on October 10, 2023 was just a warning, this alert is an indication that the FDA is focusing its attention on compounded ketamine and the potential dangers to patients.
Oberman Law Firm represents clients in a wide range of practice areas, including private equity, M&A, healthcare, corporate transactions, intellectual property, data privacy and security, regulatory compliance and governance, cross-border transactions, labor and employment, construction law, litigation, private clients’ services, corporate restructuring, and white-collar and governmental disputes.
As a firm, we offer the highest quality legal advice coupled with extraordinary and tailored service to deliver exceptional results to our clients. Our philosophy is to invest deeply in the brightest legal talent and build dynamic teams that operate at the pinnacle of respective practice areas. We believe in empowering our attorneys, encouraging entrepreneurialism, operating ethically and with integrity, and collaborating to bring the very best to every client engagement. These principles have guided us in building extraordinary and successful long-term partnerships with our clients.